Drug Trial Radar · NCT05565417
Study of the Monoclonal Antibody IMT-009 in Patients With Advanced Solid Tumors or Lymphomas
Last checked: Nov 19, 2026Latest source record: Oct 16, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
67
Actual
Start
Nov 28, 2022
Primary completion
Jan 2026
Study completion Jan 2026
Sponsor
- Lead sponsor
- Immunitas TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- Oct 4, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 1/2a open-label, multicenter, dose escalation and dose expansion trial in which IMT-009 will be administered by the intravenous (IV) route to participants with solid tumors or lymphomas. The main goals of this study are to: * Find the recommended dose of IMT-009 that can be safely given to participants * Learn more about the side effects of IMT-009 * Learn more about pharmacokinetics of IMT-009 * Learn more about the effectiveness of IMT-009 * Learn more about different pharmacokinetic biomarkers and how they might change in the presence of IMT-009
Conditions
- Non Small Cell Lung Cancer
- Head and Neck Squamous Cell Carcinoma
- Triple Negative Breast Cancer
- Cutaneous Squamous Cell Carcinoma
- Hormone Receptor Positive Breast Carcinoma
- Small Bowel Cancer
- Esophageal Cancer
- Colorectal Cancer
- Diffuse Large B Cell Lymphoma
- Hodgkin Lymphoma
- Burkitt Lymphoma
- Follicular Lymphoma
Interventions
IMT-009Drug
Participants will receive an IV infusion of IMT-009 on Day 1 during each 21-day cycle.
FruquintinibCombination product
Fruquintinib will be administered according to the FDA-approved United States Prescribing Information (USPI).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Dose Escalation - number of participants with dose limiting toxicities (DLTs) from IMT-009 monotherapyTime frame: 21 days (Cycle 1 Day 1- Cycle 1 Day 21)
- Dose Escalation- Number of participants with adverse events following administration of IMT-009Time frame: From informed consent (Cycle 0 Day -28) to 90 days after the last dose of IMT-009. Each cycle is 21 days
- Phase 1b Cohort(s) number of participants with dose limiting toxicities (DLTs) from IMT-009 in combination with fruiquintinibTime frame: 28 days (Cycle 1 Day 1- Cycle 1 Day 28)
- Phase 1b Cohort(s) - Number of participants with adverse events following administration of IMT-009 in combination with fruiquintinibTime frame: From informed consent (Cycle 0 Day -28) through 90 days after last dose of IMT-009. Each cycle is 28 days
- Phase 2a Cohort(s) Overall Response Rate (ORR) based on RECIST 1.1 or Lugano criteria (lymphomas only) to assess anti-tumor activity of IMT-009 in each cohortTime frame: Every 6 weeks from Cycle 1 Day 1, until disease progression or death or start of a new anti-cancer therapy, up to 2 years. Each cycle is 21 days.
Locations
9 sites in 1 country. Site status is shown where the registry gives one.
Site 9618
Tucson, Arizona
Site 5000
Denver, Colorado
Site 4100
Orlando, Florida
Site 4060
Sarasota, Florida
Site 4500
Oklahoma City, Oklahoma
Site 9280
Portland, Oregon
Site 3000
Nashville, Tennessee
Site 9384
Austin, Texas
Site 9112
Fairfax, Virginia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.